Connect with us

Opinion

How will femtech innovations change the menopause in 2025?

Published

on

By Aida Daniel, femtech and consumer insights expert at PA Consulting.

Despite being an inevitable life stage for half the population, the menopause is still largely surrounded by silence and stigma.

Last year, a UCL-led study unearthed that nine in ten postmenopausal women were never educated about it in school, leaving many woefully uninformed until experiencing it first-hand. Another survey found that over 80 per cent of women under 40 either had ‘no knowledge at all’ or just ‘some knowledge’ of the menopause.

Low levels of awareness are compounded by the fact menopause is a complex, multifaceted condition that every individual experiences differently. The array of symptoms – often drawn out over two to eight years during the transition period before menopause, called perimenopause – can leave people uncertain about when they are entering this life phase, what changes to expect, and when to seek diagnosis. This makes it hard for many women to track changes and advocate for their medical care.

And, of course, there’s the historical lack of support at a wider societal level. A recent report spotlighted that budgetary constraints and a limited focus on mid-life women’s health have led to poor UK-wide menopause provision. Meanwhile, a Fawcett Society report uncovered that 44 per cent of women’s ability to work had been affected by menopause-related symptoms and 52 per cent had lost confidence.

The lack of open, public discourse around menopause has clearly resulted in large gaps in awareness and support. But there is cause for hope. Over the course of 2024, a plethora of start-ups have been starting to plug the gap, ushering in a more proactive, empowered approach to the menopause, with personalised solutions tailored to individual needs. Looking to 2025, we can expect digital care to further transform menopause care in several important ways.

Tracking biometric data

Leading the charge in menopause innovation: health management systems that use biometric data to track personal health trends. A wave of companies are starting to bring menopause tracking to wearable tech – including Oura, Clue, Mira Care, Amira and Whoop – and are partnering with research institutions to harness this data. We can expect this to remain a central feature of 2025.

For example, working with research scientists, Oura recently examined aggregated data from over 100,000 female Oura Members on the perimenopause. By identifying how physical, physiological and mental changes impact sleep, mood, energy levels, and cardiovascular health, Oura produced a report which claims to be a step forward in its goal to innovate and evolve its technological solutions. The granularity and breadth of biometric data that new wearable technologies are poised to capture in the next 12 months will allow for even more personalised health insights, real-time monitoring, and solutions born from trend-tracking.

Non-hormonal solutions

Start-ups are also starting to offer more non-hormonal treatments for menopause symptoms. Looking to 2025, wearable technologies are set to expand to treat a larger array of acute menopause symptoms with innovative, non-hormonal solutions.

For example, this year, wellness tech start-up Amira launched ‘The Terra System’: a wearable wrist device that predicts hot flashes before they occur, activating a cooling mattress to help the user stay cool and asleep. Grace, a wearables company, is also developing the world’s first automated tracking and cooling bracelet, yet to be commercially available, designed to fend off hot flushes throughout the day. More non-hormonal solutions for areas like sleep optimisation, anxiety and stress reduction, sexual wellness, and incontinence management are likely to emerge over the next year.

AI breakthroughs

2024 has been a year of AI breakthroughs – which has set the stage for significant changes in menopause care. Take AI-powered virtual assistants. According to a new report, these could serve as an invaluable resource, equipping more women with personalised support and information relating to menopausal symptoms.

One example is Mira Care, which in 2024 launched its AI-powered ‘Menopause Transitions Kit’ for at-home hormone monitoring. It allows users to track four key reproductive hormones, using AI and digital therapeutics to personalise menopause management accordingly. AI-powered solutions like these can not only transform the ease of diagnosis of menopause, but also help people increasingly tailor menopausal treatment to their genetic, hormonal, and lifestyle factors, to maximise effectiveness and minimise side effects.

Increasingly holistic approach

Taking a holistic approach is another emerging school of thought in menopause care. Menopause is just one of the many life stages that women may go through, from puberty and menstruation to pregnancy and postpartum. Women often address symptoms and needs that come with these stages individually, but a holistic approach that considers emotional, mental, and social aspects, and nurtures the whole person, arguably has better long-term impacts.

Start-ups and organisations like The Menopause Charity and Peanut are helping people achieve this by providing tools that support not just symptom treatment, but also emotional well-being, physical health, and community building. Looking to 2025, a holistic approach to menopause care will centre on education and preparation as key tools for empowerment, as well as engaging with those experiencing the menopause during the early stages. Start-ups like NNABI, launched in 2024, have focused their resources on this key stage.

The UK’s National Menopause Education and Support Programme is also partnering with charities, researchers, and clinicians to develop and trial first-of-their-kind courses for those who have and haven’t reached perimenopause.

Privacy and trust in menopause data

Femtech innovations like these hold great promise for transforming the menopause experience. But technology can nonetheless be a double-edged sword. 59 per cent of UK women are concerned about the privacy and security of healthcare tracking apps, with transparency around how companies are using their data emerging as key issues.

These concerns are not unfounded. A UCL study found that only 1 in 20 popular female health apps in the UK and US explicitly addresses data sensitivity in their privacy policies, with 35 per cent contradicting claims of not sharing personal data with third parties, and 45 per cent disclaiming responsibility for third-party practices despite claiming to vet them.

At a time of growing awareness of the risks of personal data being accessed or leaked, businesses need to be more transparent about how data is handled in 2025, and communicate comprehensive privacy policies to drive confidence in emerging technologies.

Privacy policies should be clear, accessible, and presented at the right time during onboarding, with explicit references to how data is processed, stored, and shared. Companies must obtain consent to process data that is not necessary for their operations, such as for targeted advertisements or shared with third parties, allowing users to refuse consent or withdraw it later.

The ICO’s 2025 priorities for health and social organisations also advise organisations to be proactive in developing engaging and regular information updates to users, ensuring transparency in how personal data is used. The standards launched by the British Standards Institution on menstruation and menopause in the workplace similarly acknowledge this.

Ultimately, the journey through menopause is highly personal and complex. However, menopause tech is paving the way for healthcare tools and solutions that help address historic gaps in women’s health in the coming year.

Emerging technologies and start-ups are helping those experiencing the menopause to understand their bodies, proactively track symptoms, find personalised tailor-made solutions, and take a holistic approach to their healthcare.

With the right privacy and security considerations in place, these femtech innovations have the potential to fundamentally improve the lives of millions of women worldwide.

Aida Daniel is a femtech and consumer insights expert at PA Consulting.

News

Why advocacy-orientated CPD matters for the future of cardiology

Published

on

By Women As One

At the 2026 Alliance Annual Conference, Women As One presented a poster that asked a powerful question: What if continuing professional development (CPD) did more than teach clinical knowledge— and instead helped shape the future of the workforce itself?

For decades, professional education in medicine has focused primarily on what clinicians know and how they practice. That work remains essential.

But persistent gender gaps across cardiology—from leadership positions to research participation and speaking opportunities—demonstrate that knowledge alone is not enough to ensure equitable advancement.

To truly strengthen the field of cardiology, professional development must also support who clinicians become, the opportunities they access, and the voices that shape the future of cardiovascular medicine.

Our poster, More Than Education: Elevating Equity and Identity Through CPD, explores how a new model of advocacy-orientated CPD can help close these gaps.

Advocacy-orientated CPD expands the traditional model of professional education. In addition to building clinical expertise, it intentionally supports the structural elements that shape career advancement—mentorship, sponsorship, leadership development, visibility, and professional networks.

By integrating these elements into professional education, CPD can become a powerful engine for advancing equity—and ultimately improving patient care.

Why this matters

Gender inequities in medicine are not simply workforce issues. They influence research priorities, clinical trial representation, leadership decision-making, and ultimately the care patients receive.

When women clinicians have equitable opportunities to lead, research, and shape clinical practice, the entire healthcare system benefits.

Yet structural barriers remain. Women physicians often have less access to mentorship, sponsorship networks, and leadership pathways—factors that are critical for career advancement.

This is where advocacy-orientated CPD comes in.

By intentionally designing programs that foster mentorship, build leadership skills, create visibility, and support long-term professional growth, organizations can help ensure that the next generation of cardiovascular leaders reflects the diversity of the patients they serve.

Turning opportunity into impact

Since its founding, Women As One has supported thousands of women cardiologists across more than 100 countries, expanding access to mentorship, research opportunities, and leadership development.

Through programs like CLIMB, RISE, Mentorship Awards, and our global digital community, The Pulse, thousands of women cardiologists have gained mentorship, leadership training, and opportunities that accelerate their careers and expand their influence.

Today, the outcomes of these programs are shaping the field in tangible ways:

  • Women As One alumnae are leading clinical trials and advancing cardiovascular research
  • Clinicians supported through our programs are building registries, launching new care models, and expanding access to specialized care
  • Women cardiologists are gaining greater representation on speaker panels, advisory boards, and leadership pathways
  • A global community of more than 3,000 women cardiologists is strengthening collaboration, mentorship, and visibility across the profession

These outcomes demonstrate what becomes possible when professional development goes beyond traditional education to intentionally support leadership, identity, and community.

A call to the cardiovascular community

Advancing equity in cardiology is not the responsibility of one organization—it requires a collective effort across the entire ecosystem of clinicians, educators, institutions, and industry partners.

For women cardiologists, this means engaging in the programs, mentorship networks, and leadership opportunities that help shape the future of the field. Whether through CLIMB, RISE, research initiatives, or participation in The Pulse community, your involvement strengthens a growing movement dedicated to advancing women in cardiology.

For our partners and supporters, this work demonstrates the powerful impact that strategic investment in equity-focused professional development can have on the workforce and the patients we ultimately serve.

Together, we can redefine what professional development looks like in medicine—not just as a pathway for learning, but as a catalyst for leadership, opportunity, and lasting change.

Explore the poster

We invite you to explore the poster below (click here to download it) to learn more about the evidence, framework, and real-world impact behind this work—and to join us in continuing to expand what professional development can achieve for the future of cardiovascular medicine.

Learn more about Women As One at womenasone.org

Continue Reading

Mental health

What Maternal Mental Health Month reveals about where postpartum support actually breaks down

Published

on

By Morgan Rose, chief science officer at Ema, and Lauren Scocozza, vice president of product at Willow

May is Maternal Mental Health Month, and every year it surfaces a familiar set of statistics: 1 in 5 new mothers experiences postpartum depression or anxiety, most go unscreened, and the majority who are screened don’t receive adequate follow-up care.

The conversation is important. But the numbers obscure something that anyone who has worked in this space knows to be true: postpartum mental health distress rarely arrives with a label.

It arrives as exhaustion. As “I’m not sure I’m doing this right.”

As a question about supply, pumping, whether it’s okay to feel this disconnected from something you were supposed to love immediately.

Willow integrated Ema, AI built for women’s health, with the goal of closing the maternal care and data gap.

The pattern mentioned above appears consistently in Ema’s conversational data through the Willow app.

A mother reports mastitis symptoms.

Ema walks her through the clinical presentation, confirms she should keep pumping, and then she questions if she is using her pump correctly. In the same thread, within a few exchanges, she says she’s “feeling too sad.” Then: “I don’t know. I think I’m depressed. I am not enjoying my postpartum.”

She did not come to the app to talk about her mental health.

She came about a breast infection. The mental health disclosure came through the already-opened door.

The Weight Underneath the Technical Question

New motherhood involves an enormous amount of problem-solving at a time when cognitive and emotional reserves are depleted. The pump has to work. The baby has to eat. The body has to recover.

Work comes back. Sleep doesn’t. Feeding their babies requires skill, and the learning curve sits atop it all.

What Ema’s conversation data shows is that the emotional load of navigating these challenges is not separate from mental health. It is mental health.

When a mother writes, “I’m postpartum and overwhelmed and tired,” and then, in the same breath, asks about flange sizing, she is telling us what the postpartum experience actually feels like from the inside.

The technical question and the emotional state are one and the same.

Breastfeeding carries particular weight here.

The desire to breastfeed, the guilt when it doesn’t go as planned, and the identity questions that come with feeding choices are not peripheral to the postpartum mental health conversation.

In our conversations, women navigating supply concerns often reveal deeper anxieties: about whether they are good mothers, whether their bodies are “working,” and whether the difficulty they are experiencing means something about them.

These are the signals worth asking about.

What Screening Looks Like in Practice

Ema is trained on the Edinburgh Postnatal Depression Scale and is equipped to offer the EPDS when a conversation warrants it.

The value is being present for the moment when a woman is ready to name what she’s feeling.

That moment rarely comes as a direct request for mental health support. It comes when someone is already in a conversation about something else, and something shifts.

A woman dealing with mastitis says she feels sad. A woman worried about supply says she doesn’t feel like herself. A woman managing the logistics of going back to work with a wearable pump says she’s not sure she can keep up with it all — and the “it all” isn’t about the pump.

Ema is designed to hear that. She doesn’t stay on the clinical or technical track when the conversation moves. She follows the person.

And when the moment is right, she offers the screening as a natural next step.

In one exchange, a woman was offered the EPDS after disclosing depressive feelings. She declined.

Ema acknowledged that and asked if she wanted to talk about something else. That’s the right response. The offer was made without pressure. The door stays open.

Sometimes what matters most is that someone asked at all.

The Continuity Problem

One of the most persistent structural failures in maternal mental health care is fragmentation.

A woman sees her OB at six weeks postpartum for a brief screening. She may get a call from a nurse. She may be given a referral she never follows up on because she doesn’t have the capacity to navigate a new care relationship while managing a newborn.

The clinical touchpoints are too few, too far apart, and too often siloed from one another.

The postpartum period lasts far longer than the six-week checkup implies. Mental health symptoms can emerge weeks or months after delivery, shift in character over time, and interact with physical challenges in ways that don’t fit neatly into any single provider’s lane.

A lactation concern becomes an anxiety spiral. A supply drop triggers a grief response. A difficult return to work surfaces a postpartum depression that wasn’t fully recognized at six weeks.

Ema sits inside these moments because she’s embedded in the platform women are already using. She doesn’t require a separate appointment, a referral, or the cognitive bandwidth to seek out a new resource.

She’s in the Willow app that mom is already using multiple times a day to manage her pump.

When Ema identifies a woman who may need more support than she can provide, she routes to the right resource — whether that’s a SimpliFed lactation consultant for feeding-related concerns or a clinical professional for mental health follow-up.

The conversation leads to the handoff with someone who can do more.

What the Month of May Means for the Rest of the Year

Maternal Mental Health Month is a useful moment of attention. The awareness campaigns, the social media posts, and the statistics shared in newsletters matter.

But the gap in postpartum mental health care is not really an awareness problem.

Most people in the perinatal space and beyond know the statistics. The problem is access, timing, and continuity.

AI doesn’t close that gap on its own.

What it can do is be present in the spaces where women already are, at the times when they need something, and attentive enough to recognise that a conversation about a pump, a clogged duct, or a supply concern is also a conversation about how someone is doing.

The question behind the question is often the more important one.

For Willow, the conversation data Ema generates is a map of where mothers are struggling, what they reach for when they need help, and when they are ready to say more than they came to say.

That information, used well, shapes better resources, better onboarding, and a more connected experience across the full arc of the postpartum year and beyond.

Building the infrastructure to support maternal mental health is a year-round project.

Willow is doing one part of that, and the conversations happening on the Willow platform every day are evidence that women want support that meets them where they are… in their app, in their moment, without having to ask for it twice.

About the authors

Morgan Rose is Chief Science Officer at Ema, an AI platform for women’s health. Ema partners with healthcare organisations and femtech companies to deliver clinically grounded AI support across the perinatal journey.

Lauren Scocozza is the Vice President of Product at Willow Innovations, Inc. For women by women, Willow is building a maternal care platform to address the interconnected challenges of postpartum.

Continue Reading

Opinion

Femtech’s next chapter: Building a truly equal and comprehensive health tech category

Published

on

By Wolfgang Hackl, MD, CEO OncoGenomX, Allschwil, Switzerland

FemTech is moving from a promising niche to a foundational part of modern healthcare.

Over the next decade and beyond, its real promise will not only be better products, but a more equitable system: one where women’s health is treated as an equal area for innovation, investment, clinical care, and public policy.

That shift matters because women’s health has long been under-researched, underfunded, and too often managed through systems that were not designed with female biology and life stages in mind.

The opportunity now is to change that trajectory.

If stakeholders act deliberately, FemTech can become a category that improves outcomes, expands access, and creates measurable value across the HealthTech ecosystem.

From niche to infrastructure

The most important change ahead is a mindset shift. FemTech should no longer be seen as a narrow consumer segment focused only on logging symptoms.

It should be understood as health infrastructure spanning puberty, fertility, pregnancy, postpartum recovery, menopause, pelvic health, chronic disease, mental health, and long-term preventive care.

This broader framing creates a more durable market and a stronger social case. It also encourages innovation that serves people across the full life course, rather than only at highly visible moments.

In practical terms, this means building tools that are clinically relevant, integrated into care pathways, and designed to work for different populations and health systems.

What needs to change

For FemTech to become a truly equal healthcare category and a genuine societal priority, several layers need to move together.

First, the evidence base must deepen. More sex-disaggregated data, more women-inclusive clinical studies, and more research on conditions that disproportionately affect women are essential.

Without stronger evidence, product development, diagnosis, reimbursement, and clinical adoption all remain constrained.

Second, policy and regulation must mature. Privacy protections need to be strong enough to build trust in highly sensitive health data.

Regulatory pathways should be clear enough to help innovators bring safe, effective products to market without unnecessary delay.

Reimbursement frameworks also need to evolve so that useful digital tools are not limited to those who can pay out of pocket.

Third, healthcare systems must become more open to integration. The best FemTech products should not sit outside the care journey as standalone apps.

They should connect with clinicians, diagnostics, telehealth, and care coordination so that patients experience continuity rather than fragmentation.

Finally, society needs a broader cultural shift. Women’s health should be discussed as a mainstream public health and economic issue, not as a side topic or a private concern.

That means normalizing conversations around menopause, miscarriage, postpartum health, chronic pain, infertility, and long-term preventive care.

The role of each stakeholder

A healthier FemTech future depends on the full value chain.

Founders and product teams need to design for clinical relevance, usability, and trust. The strongest solutions will be those that solve real problems, use data responsibly, and fit into everyday life and care.

Investors can help by backing long-term value creation rather than only consumer growth. FemTech deserves capital that supports rigorous validation, regulatory readiness, and scalable business models.

Healthcare providers and systems play a critical role in adoption. By integrating FemTech into clinical workflows, they can reduce delays in care, improve monitoring, and make support more continuous and personalised.

Payers and insurers can accelerate access by recognising the downstream value of early intervention, prevention, and better self-management. Coverage decisions will strongly shape which innovations become standard practice.

Policymakers and regulators should create environments where safety, innovation, and privacy coexist. Clear standards and supportive reimbursement policy can make the difference between isolated success and category-wide growth.

Employers and public institutions also have a role. Women’s health affects productivity, retention, and long-term wellbeing, which means workplace benefits and public programs can help expand access and reduce inequity.

FemTech is not only “women for women.” It is “everyone to solve a health and social issue that has been ignored for far too long.”

When stakeholders across the value chain recognise women’s health as a shared responsibility, FemTech moves from a segmented category to a mainstream force for better outcomes, fairer access, and stronger social impact.

Why the upside is larger than the market

The benefit of getting this right is not only commercial.

Better women’s health tools can improve early detection, support self-management, reduce avoidable complications, and lower the burden on social and healthcare systems.

They can also help close persistent gaps in access and outcomes that affect families, workplaces, and economies.

For HealthTech innovators, this is an opportunity to build products that are both mission-driven and scalable. For health systems, it is a chance to improve care quality and efficiency. For society, it is a way to move women’s health from an afterthought to an equal priority.

Actions that will move the field forward

The right direction will not happen automatically. It requires deliberate action across the ecosystem.

  • Build products around real clinical needs, not only consumer engagement.
  • Invest in women-inclusive research and validation from the start.
  • Design privacy and governance into the product architecture.
  • Create reimbursement models that reward prevention and continuity.
  • Integrate FemTech into mainstream care pathways.
  • Expand education for clinicians, employers, and the public.
  • Expand the category to the invisible concerns to cover the full range of women’s health needs.

When these actions align, FemTech can mature into something larger than a market category. It can become a model for how health innovation should work: evidence-based, inclusive, trusted, and built to improve lives at scale.

A strong FemTech future is not just possible. It is a practical next step if the ecosystem chooses to treat women’s health as what it truly is: a core healthcare priority and a major driver of innovation.

Table: FemTech Focus Areas

FieldApproximate number of active solutions/companies
Reproductive health & fertility120+
Pregnancy & maternal care80+
Menstrual health60+
General women’s health & wellness50+
Diagnostics & monitoring45+
Menopause & perimenopause40+
Pelvic & uterine health30+
Chronic women’s health / integrated care30+
Sexual health & wellness25+

Legend: FemTech is becoming a multi-category healthcare layer. Reports also show that software/apps remain the largest product type overall, while reproductive health continues to dominate as an application area. Best-effort estimates based on category listings, company directories, and market reports, not audited totals.

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.